Brokers Offer Predictions for MLTX FY2029 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Investment analysts at Leerink Partnrs issued their FY2029 EPS estimates for MoonLake Immunotherapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will earn $8.17 per share for the year. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

Several other brokerages also recently commented on MLTX. The Goldman Sachs Group upgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $62.00 to $82.00 in a research note on Friday, January 17th. Wedbush restated an “outperform” rating and issued a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $84.29.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX stock opened at $45.06 on Friday. The stock’s fifty day simple moving average is $49.88 and its 200 day simple moving average is $49.02. MoonLake Immunotherapeutics has a one year low of $37.55 and a one year high of $64.98. The firm has a market cap of $2.88 billion, a price-to-earnings ratio of -34.93 and a beta of 1.29.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same period last year, the business earned ($0.18) earnings per share.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Institutional investors have recently modified their holdings of the stock. US Bancorp DE bought a new stake in shares of MoonLake Immunotherapeutics during the third quarter valued at approximately $44,000. Barclays PLC boosted its position in MoonLake Immunotherapeutics by 1,269.2% in the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after buying an additional 5,229 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of MoonLake Immunotherapeutics by 3.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company’s stock valued at $460,000 after buying an additional 320 shares during the period. Handelsbanken Fonder AB raised its holdings in MoonLake Immunotherapeutics by 26.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock worth $655,000 after purchasing an additional 2,700 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at $706,000. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.